Skip to content
Screener

Solid Biosciences Inc. SLDB Q1 2026 earnings

Reported May 12, 2026 · Before market open

EPS-$0.52Miss by $0.12
EPS estimate-$0.40

Next report

Nov 2, 2026 (in a month)
EPS estimate-$0.37

Financials

Q1 2026

Income statement

See full
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$708.42M+147%
Enterprise value$431.98M+333%

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

FAQ

When did Solid Biosciences Inc. report Q1 2026 earnings?
Solid Biosciences Inc. (SLDB) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Solid Biosciences Inc.'s Q1 2026 revenue and EPS?
Solid Biosciences Inc. reported eps of $-0.52 for Q1 2026.
Did Solid Biosciences Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.40 by $0.12.
How did Solid Biosciences Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 11.9% from $-0.59.
Where can I find Solid Biosciences Inc.'s Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001193125-26-219337) directly on SEC EDGAR. The filing index links above go to sec.gov.